Clinical Trial Update: RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of everolimus (RAD001) in patients with chronic phase chronic myeloid leukemia with molecular disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Chronic Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN